Aligos Therapeutics (ALGS) Stock Price, Quote, News & History | Benzinga

SPY777.54−0.07%QQQ742.87−0.42%BTC/USD83,231.73+0.16%DIA515.75−0.42%GLD380.96−0.31%TLT78.41+0.46%

Aligos Therapeutics Inc (ALGS) Stock Price, Quote, News & History

ALGSNASDAQ

Trade with Public

Trade with Public

$5.51

-0.02-0.36%

Last update: Oct 13, 4:00 PM

$5.53

N/A

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

-

Close

$5.51

Volume / Avg.

33.85K / 87.43K

Day Range

$5.51 - $5.51

52 Wk Range

3.98 - 13.69

Market Cap

$34.53M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

13.36%

Days to Cover

14.35

Recent Aligos Therapeutics, Inc. News

Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.

Avi Kapoor

Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.

Avi Kapoor

Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock

Aligos Therapeutics stock rose in after-hours trading after a $25 million licensing payment and China Breakthrough Therapy designation.

Tanya Rawat

Why Akamai Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket

Akamai Technologies Inc (NASDAQ: AKAM) rose in pre-market trading after reporting strong Q1 results and raising FY26 sales guidance.

Avi Kapoor

Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates

Aligos shares rise after China licensing deal for HBV drug; milestones, trial updates, and technical levels shape investor outlook.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-94.17M

Investing Cash Flow (TTM)

105.59M

Financing Cash Flow (TTM)

228.00K

Free Cash Flow (TTM)

-94.52M

Capital Expenditure (TTM)

-355.00K

Net Change in Cash (TTM)

11.65M

Analyst Trends and Forecast

2

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.47M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.82

PB Ratio (TTM)

1.08

Earnings Yield % (TTM)

-139.42%

Earnings Yield % (FWD)

-79.02%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.11

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$91.00K

Total Cash

$30.38M

Debt to Equity

0.11

Issuance of Debt (TTM)

-$91.00K

Repayment of Debt (TTM)

-$91.00K